Beta
SGLT2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin)
medication Under reviewSGLT2 inhibitors are a class of prescription medications that block the sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption in the proximal tubule and increasing urinary glucose excretion. By promoting glycosuria, they lower blood glucose levels, modestly reduce body weight, and induce a mild osmotic diuresis and natriuresis, which can influence blood pressure and fluid status. Empagliflozin, dapagliflozin, and canagliflozin are among the most widely studied agents in this class. Beyond glycemic control, SGLT2 inhibitors have important cardiovascular and renal effects. Large randomized trials in patients with and without diabetes have shown reductions in heart failure hospitalizations, cardiovascular death, and progression of chronic kidney disease. These benefits appear to be partly independent of blood glucose lowering and are thought to involve changes in renal hemodynamics, improved cardiac loading conditions, and metabolic shifts such as increased ketone utilization. In healthy individuals, short-term studies primarily document predictable pharmacodynamic effects on glucose handling, urinary output, and hemodynamics rather than direct therapeutic benefits. Because SGLT2 inhibitors are potent prescription drugs with risks including genital infections, urinary tract infections, volume depletion, and diabetic ketoacidosis, they are not typically used in healthy people without diabetes or heart failure. Most data in humans come from patients with cardiometabolic disease, and any extrapolation to healthy populations must be made with caution. Use in otherwise healthy subjects has mainly occurred in phase 1 trials designed to characterize pharmacokinetics, pharmacodynamics, and safety at various doses.
Research summary
Human research on empagliflozin, dapagliflozin, and canagliflozin is extensive in populations with type 2 diabetes, heart failure, and chronic kidney disease, consistently showing cardiovascular and renal benefits together with glucose-lowering effects. Randomized controlled trials and meta-analyses indicate that individual agents have broadly similar efficacy for reducing major cardiovascular and kidney outcomes, and some analyses include participants without diabetes, demonstrating comparable reductions in heart failure events and kidney disease progression in those higher-risk but non-diabetic groups. In truly healthy volunteers, available studies are early-phase trials focused on pharmacodynamic responses rather than long-term health outcomes. These trials show predictable increases in urinary glucose excretion, reductions in postprandial glucose excursions, mild changes in blood pressure, and increased urine volume, with a safety profile dominated by genital and urinary tract infections and occasional volume-related symptoms. There is currently no evidence base supporting use of SGLT2 inhibitors as a preventive supplement in healthy adults, and expert reviews that speculate on primary prevention emphasize that such an indication would require dedicated trials and careful risk–benefit evaluation.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Comparison of canagliflozin to other SGLT2 inhibitors in healthy subjects
Henry RR, Rosenstock J, Edelman SV, et al.
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.
Heise T, Seewaldt-Becker E, Macha S, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Safety, tolerability and pharmacodynamics of dapagliflozin in healthy subjects
Kasichayanula S, Liu X, Benito P, et al.
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.
Heise T, Seewaldt-Becker E, Macha S, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.
Heise T, Seewaldt-Becker E, Macha S, et al.
Safety, tolerability and pharmacodynamics of dapagliflozin in healthy subjects
Kasichayanula S, Liu X, Benito P, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.
Heise T, Seewaldt-Becker E, Macha S, et al.
Safety, tolerability and pharmacodynamics of dapagliflozin in healthy subjects
Kasichayanula S, Liu X, Benito P, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Comparison of canagliflozin to other SGLT2 inhibitors in healthy subjects
Henry RR, Rosenstock J, Edelman SV, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Sglt2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) to your stack to report effects
Comparison of canagliflozin to other SGLT2 inhibitors in healthy subjects
Henry RR, Rosenstock J, Edelman SV, et al.
Research (3 studies)
Comparison of canagliflozin to other SGLT2 inhibitors in healthy subjects
Henry RR, Rosenstock J, Edelman SV, et al.
Safety, tolerability and pharmacodynamics of dapagliflozin in healthy subjects
Kasichayanula S, Liu X, Benito P, et al.
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.
Heise T, Seewaldt-Becker E, Macha S, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!